Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells

Molecular Endocrinology

Volumn 27, Issue 9, 2013, Pages 1429-1441

  Docquier, Aurélie ^a   Garcia, Aurélie ^a   Savatier, Julien ^b   Boulahtouf, Abdel ^a   Bonnet, Sandrine ^a   Bellet, Virginie ^a   Busson, Muriel ^a   Margeat, Emmanuel ^a,b   Jalaguier, Stéphan ^a   Royer, Cathy ^b   Balaguer, Patrick ^a   Cavaillès, Vincent ^a  

^a U896 Université Montpellier1 and Institut ré gional du Cancer Montpellier Montpellier ^*  (France)

^b CENTRE DE BIOCHIMIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HETERODIMER; MESSENGER RNA; RECEPTOR INTERACTING PROTEIN 140; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; FLUORESCENCE ANALYSIS; GENE OVEREXPRESSION; GENE SILENCING; HOMEOSTASIS; HUMAN; HUMAN CELL; MITOGENICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LIGANDS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84883213001     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1351     Document Type: Article

References (53)

1. Harris HA. Estrogen receptor-β: recent lessons from in vivo studies. Mol Endocrinol. 2007;21:1-13.
2. Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol. 2004;50:3-22.
3. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81: 1535-1565.
4. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER α and ER β. Mol Interv. 2003;3:281-292.
5. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ER α or ERβ. J Cell Biochem. 2003;90:315-326.
6. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor α and β heterodimers exert unique effects on estrogen-and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol. 2005;19:1555-1568.
7. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER)α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology. 2004;145:3473-3486.
8. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905-931.
9. Bai J, Uehara Y, Montell DJ. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell. 2000;103:1047-1058.
10. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, et al. Inducible upregulation of oestrogen receptor-1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol. 2005;34:553-566.
11. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004;101:1566-1571.
12. Sotoca AM, Ratman D, van der Saag P, Ström A, Gustafsson JA, Vervoort J, et al. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ ERβ ratio. J Steroid Biochem Mol Biol. 2008;112:171-178.
13. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Ström A, Gustafsson JA, et al. Influence of cellular ERα/ERβ ratio on the ERα-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci. 2008;105:303-311.
14. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
15. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor α (ER-β) and α (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-α in neoplastic tissues. J Clin Endocrinol Metab. 1998;83:1025-1028.
16. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, et al. Differential expression of estrogen receptor-α and-β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 1998;58:5367-5373.
17. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A, Mor G. Absence of estrogen receptor-α expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96:417-421.
18. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol. 2008;111:144-151.
19. Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, Györffy B, et al. Loss of estrogen receptorβ expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res. 2011;31: 711-718.
20. Drummond AE, Fuller PJ. The importance of ERα signalling in the ovary. J Endocrinol. 2010;205:15-23.
21. Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, et al. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor α or β. Biochem Pharmacol. 2006;71: 1459-1469.
22. Docquier A, Augereau P, Lapierre M, Harmand P-O, Badia E, Annicotte J-S, et al. The RIP140 gene is a transcriptional target of E2F1. PLoS ONE. 2012;7:e35839.
23. Castet A, Boulahtouf A, Versini G, Bonnet S, Augereau P, Vignon F, et al. Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibition. Nucleic Acids Res. 2004;32: 1957-1966.
24. Thénot S, Bonnet S, Boulahtouf A, Margeat E, Royer CA, Borgna JL, et al. Effect of ligand and DNA binding on the interaction between human transcription intermediary factor 1α and estrogen receptors. Mol Endocrinol. 1999;13:2137-2150.
25. Savatier J, Jalaguier S, Ferguson ML, Cavaillès V, Royer CA. Estrogen receptor interactions and dynamics monitored in live cells by fluorescence cross-correlation spectroscopy. Biochemistry. 2010; 49:772-781.
26. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA, et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer. 1989; 63:280-288.
27. Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, et al. Transcriptional regulation of the human NRIP1/ RIP140 gene by estrogen is modulated by dioxin signalling. Mol Pharmacol. 2006;69:1338-1346.
28. Augereau P, Badia E, Carascossa S, Castet A, Fritsch S, Harmand PO, et al. The nuclear receptor transcriptional coregulator RIP140. Nucl Recept Signal. 2006;4:e024.
29. Carascossa S, Gobinet J, Georget V, Lucas A, Badia E, Castet A, et al. Receptor-interacting protein 140 is a repressor of the androgen receptor activity. Mol Endocrinol. 2006;20:1506-1518.
30. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995;14:3741-3751.
31. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387:733-736.
32. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537-551.
33. Lazennec G. Estrogen receptor β, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 2006;231:151-157.
34. Leitman DC, Paruthiyil S, Vivar OI, Saunier EF, Herber CB, Cohen I, et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol. 2010;10:629-636.
35. Thomas CG, Strom A, Lindberg K, Gustafsson JA. Estrogen receptor β decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Res Treat. 2011;127:417-427.
36. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol. 2007;193:421-433.
37. Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, Tagliaferri M, et al. Estrogen receptor β1 binds to and regulates three distinct classes of target genes. J Biol Chem. 2010;285:22059-22066.
38. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64:423-428.
39. Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, et al. Potential role of estrogen receptor β as a tumor suppressor of epithelial ovarian cancer. PLoS ONE. 2012;7: e44787.
40. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology. 1997;138:863-870.
41. Delaunay F, Pettersson K, Tujague M, Gustafsson JA. Functional differences between the amino-terminal domains of estrogen receptors α and β. Mol Pharmacol. 2000;58:584-590.
42. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor β and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54:105-112.
43. Papoutsi Z, Zhao C, Putnik M, Gustafsson JA, Dahlman-Wright K. Binding of estrogen receptor α/β heterodimers to chromatin in MCF-7 cells. J Mol Endocrinol. 2009;43:65-72.
44. Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERα/β heterodimer emulates functions of the ERα dimer in genomic estrogen signaling pathways. Mol Cell Biol. 2004;24:7681-7694.
45. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors α and β form heterodimers on DNA. J Biol Chem. 1997;272: 19858-19862.
46. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, et al. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. PLoS ONE. 2012;7:e30993.
47. Madak-Erdogan Z, Charn TH, Jiang Y, Liu ET, Katzenellenbogen JA, Katzenellenbogen BS. Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol. 2013;9:676.
48. Kouzu-Fujita M, Mezaki Y, Sawatsubashi S, Matsumoto T, Yamaoka I, Yano T, et al. Coactivation of estrogen receptor β by gonadotropin-induced cofactor GIOT-4. Mol Cell Biol. 2009;29: 83-92.
49. Wärnmark A, Almlö T, Leers J, Gustafsson JA, Treuter E. Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERα and ERβ. J Biol Chem. 2001;276: 23397-23404.
50. García Pedrero JM, Del Rio B, Martínez-Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol. 2002;16:947-960.
51. García-Pedrero JM, Kiskinis E, Parker MG, Belandia B. The SWI/ SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells. J Biol Chem. 2006; 281:22656-22664.
52. Nassa G, Tarallo R, Guzzi PH, Ferraro L, Cirillo F, Ravo M, et al. Comparative analysis of nuclear estrogen receptor α and β interactomes in breast cancer cells. Mol Biosyst. 2011;7:667-676.
53. Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavaillès V. The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res. 2010;16:2959-2970.